These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1474 related articles for article (PubMed ID: 28765325)

  • 41. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 42. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
    Nesic K; Krais JJ; Wang Y; Vandenberg CJ; Patel P; Cai KQ; Kwan T; Lieschke E; Ho GY; Barker HE; Bedo J; Casadei S; Farrell A; Radke M; Shield-Artin K; Penington JS; Geissler F; Kyran E; Betsch R; Xu L; Zhang F; Dobrovic A; Olesen I; Kristeleit R; Oza A; McNeish I; Ratnayake G; Traficante N; ; DeFazio A; Bowtell DDL; Harding TC; Lin K; Swisher EM; Kondrashova O; Scott CL; Johnson N; Wakefield MJ
    Mol Cancer; 2024 Aug; 23(1):158. PubMed ID: 39103848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
    Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W; Figg WD
    Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
    Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
    Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
    Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
    Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
    Bouwman P; Jonkers J
    Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
    Harvey-Jones E; Raghunandan M; Robbez-Masson L; Magraner-Pardo L; Alaguthurai T; Yablonovitch A; Yen J; Xiao H; Brough R; Frankum J; Song F; Yeung J; Savy T; Gulati A; Alexander J; Kemp H; Starling C; Konde A; Marlow R; Cheang M; Proszek P; Hubank M; Cai M; Trendell J; Lu R; Liccardo R; Ravindran N; Llop-Guevara A; Rodriguez O; Balmana J; Lukashchuk N; Dorschner M; Drusbosky L; Roxanis I; Serra V; Haider S; Pettitt SJ; Lord CJ; Tutt ANJ
    Ann Oncol; 2024 Apr; 35(4):364-380. PubMed ID: 38244928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.
    Yuan H; Xiu L; Li N; Li Y; Wu L; Yao H
    J Gynecol Oncol; 2024 Jul; 35(4):e51. PubMed ID: 38246184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
    Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.